Figure 2

Cytotoxicity of peptide-stimulated PBMCs from HLA-A3 supertype+ prostate cancer patients. Peptide-stimulated PBMCs from HLA-A3 supertype+ prostate cancer patients were tested for their cytotoxicity towards three different targets by a 6-h 51Cr-release assay. Phytohaemagglutinin (PHA)-stimulated T-cell blasts from HLA-A3 supertype+ healthy donors were used as a control. *Statistically significant at P<0.05.